News

Scotland: £60m for genomic medicine
Enlarge image

FundingUK

Scotland: £60m for genomic medicine

29.08.2012 - A pioneering genetics research centre at the University of Edinburgh receives £60m (€75,6m) funding from the Medical Research Council (MRC).

The university has also received a £3.5m (€4,4m) award from the Wellcome Trust and Wolfson Foundation to help fund the building of a new systems medicine centre. The MRC funding will be used to fund research at Edinburgh's MRC Human Genetics Unit and the MRC Institute of Genetics and Medicine (IGMM) into a range of conditions, such as schizophrenia, cystic fibrosis, and genetic eye disorders, and to develop and test new therapies. IGMM is a partnership between the MRC, the University of Edinburgh's Centre for Molecular Medicine, and Cancer Research UK.

“This funding will help us to turn the potential of the genetic revolution into reality” said Institute director Nick Hastie in a video. He explained that most of the money would continue to fund ongoing programmes in the Human Genetics Unit, but that “ten to twenty percent, combined with money from the University of Edinburgh, will allow us to do exciting new science”. This would include recruiting top researchers, purchasing new equipment, developing a brand new PhD programme and helping the centre to integrate its research with the NHS. Professor Hastie said that the ‘big aim’ was to bring the results of research into clinical practice to aid the diagnosis and treatment of disease.

The £3.5m in funding from the Wellcome Trust and the Wolfson Foundation, awarded under the Wellcome-Wolfson Capital Awards programme, will support a new systems medicine building with the construction set to start in 2013 at Edinburgh's Western General Hospital. The five-story systems medicine building will total 2,700 meters squared, and will "create a physical and intellectual bridge between centres that make up the IGMM. In addition to research spaces, the facility will include spaces for computational biology, a seminar room, offices, and an "open design" to encourage research collaborations, according to IGMM. The remainder of the estimated £10.2m for the systems medicine facility will be provided by the University of Edinburgh and the MRC.

http://www.european-biotechnology-news.com/news/news/2012-03/scotland-pound60m-for-genomic-medicine.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • 4SC (D)3.25 EUR8.33%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-7.56%
  • RENEURON (UK)3.50 GBP-5.41%
  • OXFORD BIOMEDICA (UK)5.62 GBP-4.91%

TOP

  • GALAPAGOS (B)52.00 EUR31.0%
  • NICOX (F)10.91 EUR25.0%
  • GENMAB (DK)1183.00 DKK21.8%

FLOP

  • MOBERG PHARMA (S)38.60 SEK-21.9%
  • BIONOR PHARMA (N)0.68 NOK-20.0%
  • BIOCARTIS GROUP NV (B)8.15 EUR-19.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.00 SEK1939.5%
  • NICOX (F)10.91 EUR480.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-88.6%
  • BB BIOTECH (D)43.82 EUR-84.7%
  • BIOTEST (D)17.14 EUR-78.0%

No liability assumed, Date: 27.05.2016